AltMountain

SV Biotech Crossover Opportunities Fund LP

London, United Kingdom · CIK 1903934
Offshore
Status: no Form D since Jan 2022. Funds file a Form D when they begin selling and amend it each year while the offering continues, so this fund has most likely stopped raising money. It may still be investing, or it may have closed or been dissolved. The details below are from its latest filing, kept here as a record.

SV Biotech Crossover Opportunities Fund LP is a venture capital fund based in London, United Kingdom. According to its most recent Form D, filed Jan 18, 2022, it has sold $135,180,000 of interests to 7 investors since its first sale in Dec 2021. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include SV Bco I GP LLP; SV Health Managers LLP; Nicola Trbovic.

Total raised
$135,180,000Cumulative sales reported on Form D
Investors
7
First sale
Dec 31, 2021
Minimum investment
None set
Who can invest
Qualified purchasersSection 3(c)(7): generally $5M+ in investments
Offering exemption
Rule 506(b)No general advertising
Key people and entities
SV Bco I GP LLP; SV Health Managers LLP; Nicola Trbovic
Latest Form D
Jan 18, 2022

From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠

Questions about SV Biotech Crossover Opportunities Fund LP

What is the minimum investment for SV Biotech Crossover Opportunities Fund LP?

SV Biotech Crossover Opportunities Fund LP's latest Form D, filed Jan 18, 2022, does not set a minimum investment. Managers can still require one in the offering documents.

Who can invest in SV Biotech Crossover Opportunities Fund LP?

SV Biotech Crossover Opportunities Fund LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.

How much has SV Biotech Crossover Opportunities Fund LP raised?

SV Biotech Crossover Opportunities Fund LP reports $135,180,000 sold from 7 investors on its Form D filed Jan 18, 2022. This is cumulative sales since the offering began, not current assets or performance.

Where is SV Biotech Crossover Opportunities Fund LP based?

SV Biotech Crossover Opportunities Fund LP is based in London, United Kingdom.

When did SV Biotech Crossover Opportunities Fund LP launch?

SV Biotech Crossover Opportunities Fund LP reports its first sale in Dec 2021.

Size compared with every venture capital fund

Raised more than 93% of the 43 venture capital funds based in United Kingdom, and more than 98% of all 14,864 that report sales.

Other funds with the same team

More venture capital funds in London

Similar-size venture capital funds in United Kingdom

All venture capital funds in United Kingdom